LeeWLCheungAMCapeDImpact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care2000; 23: 962–8.
2.
BoothGLKapralMKFungKRelation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet2006; 368: 29–36.
3.
Lloyd-JonesDMLeipEPLarsonMGPrediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation2006; 113: 791–8.
4.
GersteinHC.Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev2002; 18 (suppl 3): S82–S85.
5.
BhattacharyyaOKShahBRBoothGL.Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ2008; 179 (9): 920–6.
6.
GaedePVedelPLarsenNMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003; 348: 383–93.
7.
GaedePLund-AndersenHParvingHEffect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008; 358: 580–91.
8.
Final report on the aspirin component of the ongoing Physicians ‘Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med1989; 321: 129–35.
9.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ2002; 324: 71–86.
10.
ChanACampbellNLewanczukR2008 Canadian Hypertension Education Program Guidelines for the management of hypertension by pharmacists. Can Pharm J2008; 141 (6): 327–31.
11.
CampbellN. Hypertension. In: GrayJ, editor. Therapeutic choices.5th ed.Ottawa (ON): Canadian Pharmacists Association; 2007. p. 405–31.
12.
YusufSTeoKKPogueJFor the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med2008; 358: 1547–59.
13.
Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA2000; 283: 1967–75.
14.
TsuyukiRArnoldJ.The Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: a summary for pharmacists. Can Pharm J2008; 141 (2): 98–101.
15.
GutierrezCBlanchardD.Diastolic heart failure: challenges of diagnosis and treatment. Am Fam Physician2004; 69: 2609–16.
16.
HayatSAPatelBKhatterRDiabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clinical Science2004; 107: 539–57.
17.
Glucophage monograph. In: RepchinskyC, editor. Compendium of pharmaceuticals and specialties.Ottawa (ON): Canadian Pharmacists Association; 2008.
18.
ArnoldJMHowlettJGDorianPCanadian Cardiovascular Society Consensus Conference Guidelines on Heart Failure — 2008 update. Best practices for the transition of care of heart failure patients and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol2008; 24 (1): 21–40.
19.
PearsonGThompsonASemchukW.Guidelines for the management of dys-lipidemia and prevention of cardiovascular disease by pharmacists. Can Pharm J2008; 141 (Suppl 2): S11–S16.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes2008; 32 (suppl 1): S1–201. Available: www.diabetes.ca/for-professionals/resources/2008-cpg/ (accessed November 9, 2008).
